153 related articles for article (PubMed ID: 36920230)
1. Model-Informed Clinical Practice - Determining an Appropriate Ampicillin-Sulbactam Redosing Regimen in Surgical Patients by Utilizing Population Pharmacokinetics and Target Attainment Analysis.
Reeder JA; O'Sullivan CT; Xu M; Wu N; Ince D; Rogers WK; An G
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0124822. PubMed ID: 36920230
[TBL] [Abstract][Full Text] [Related]
2. Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation.
Lasko MJ; Serrano OK; Kois AK; Nicolau DP; Kuti JL
Surg Infect (Larchmt); 2022 Mar; 23(2):119-126. PubMed ID: 34818052
[No Abstract] [Full Text] [Related]
3. Prostatic Pharmacokinetic/Pharmacodynamic Evaluation of Ampicillin-Sulbactam for Bacterial Prostatitis and Preoperative Prophylaxis.
Onita T; Ikawa K; Nakamura K; Nishikawa G; Kobayashi I; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
J Clin Pharmacol; 2021 Jun; 61(6):820-831. PubMed ID: 33314138
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Soto E; Shoji S; Muto C; Tomono Y; Marshall S
Br J Clin Pharmacol; 2014 Mar; 77(3):509-21. PubMed ID: 24102758
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients.
Setiawan E; Cotta MO; Abdul-Aziz MH; Widjanarko D; Sosilya H; Lukas DL; Wallis SC; Parker S; Roberts JA
Clin Pharmacokinet; 2023 Apr; 62(4):573-586. PubMed ID: 36853585
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including
Onita T; Ikawa K; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830214
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
[TBL] [Abstract][Full Text] [Related]
9. Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.
Majcher-Peszynska J; Loebermann M; Klammt S; Frimmel S; Mundkowski RG; Welte T; Reisinger EC; Drewelow B;
Infection; 2014 Feb; 42(1):79-87. PubMed ID: 23904004
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Prophylactic Ampicillin-Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Yamamoto H; Imoto Y; Morikawa N; Takeda Y
Biol Pharm Bull; 2015; 38(11):1817-21. PubMed ID: 26521833
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
Jaruratanasirikul S; Nitchot W; Wongpoowarak W; Samaeng M; Nawakitrangsan M
Eur J Pharm Sci; 2019 Aug; 136():104940. PubMed ID: 31132402
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery.
Yokoyama Y; Matsumoto K; Yamamoto H; Iguro Y; Imoto Y; Ikawa K; Morikawa N; Ishida S; Okano Y; Watanabe E; Shimodozono Y; Yamada K; Takeda Y
J Infect Chemother; 2012 Dec; 18(6):878-82. PubMed ID: 22644082
[TBL] [Abstract][Full Text] [Related]
13. Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.
Ji XW; Zhu X; Li Y; Xue F; Kuan IHS; He QF; Meng XR; Xiang XQ; Cui YM; Zheng B
Front Pharmacol; 2022; 13():856792. PubMed ID: 35924047
[No Abstract] [Full Text] [Related]
14. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
17. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment.
Dong Y; Li Y; Zhang Y; Zhang T; Zhu L; Dong Y; Wang T
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):353-359. PubMed ID: 31056857
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
Jaruratanasirikul S; Wongpoowarak W; Wattanavijitkul T; Sukarnjanaset W; Samaeng M; Nawakitrangsan M; Ingviya N
Antimicrob Agents Chemother; 2016 Dec; 60(12):7236-7244. PubMed ID: 27671056
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Onita T; Ikawa K; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
Pediatr Infect Dis J; 2022 May; 41(5):411-416. PubMed ID: 35195566
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.
Alexov M; Lister PD; Sanders CC
Antimicrob Agents Chemother; 1996 Nov; 40(11):2468-77. PubMed ID: 8913448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
